Clinical analysis of hydroxycodone hydrochloride sustained-release tablets in the treatment of pain in advanced malignant tumors
盐酸羟考酮缓释片治疗中晚期恶性肿瘤疼痛的临床分析

摘要

目的 观察分析对中晚期恶性肿瘤患者实施盐酸羟考酮缓释片治疗的临床效果和应用价值。方法 采用回顾性研究方法，选择院内就诊的60例中晚期恶性肿瘤患者（样本纳入例数：60例；样本纳入时间：2022年5月至2023年5月），以随机摸球为基础分组方式，分为对照、实验两个小组，观察例数高度一致。分别实施常规盐酸吗啡缓释片治疗，盐酸羟考酮缓释片治疗。收集分析治疗效果。结果 与对照组（常规盐酸吗啡缓释片治疗）相比，实验组（盐酸羟考酮缓释片治疗）治疗后的致痛因子水平（血清5-羟色胺/缓激肽/脑脊液神经肽 Y）更低，生活质量评分（角色功能/情绪功能/认知功能/社会功能/躯体功能）更高，疼痛程度评分更低，（P<0.05）。结论 盐酸羟考酮缓释片治疗可以有效缓解中晚期恶性肿瘤患者疼痛程度，减少致痛因子水平，促进生活质量改善，有较高应用价值。

Abstract

Objective: Observation and analysis of the clinical efficacy and application value of hydroxycodone hydrochloride sustained-release tablets in the treatment of patients with advanced malignant tumors. Method: A retrospective study was conducted to select 60 patients with advanced malignant tumors who visited the hospital (sample size: 60 cases; sample inclusion time: May 2022 to May 2023). They were randomly divided into two groups based on ball touching, control and experimental, with a highly consistent number of observed cases. Routine morphine hydrochloride sustained-release tablets and hydroxycodone hydrochloride sustained-release tablets were administered separately. Collect and analyze treatment outcomes. Result: Compared with the control group (treated with conventional morphine hydrochloride sustained-release tablets), the experimental group (treated with hydroxycodone hydrochloride sustained-release tablets) had lower levels of pain inducing factors (serum serotonin/bradykinin/cerebrospinal fluid neuropeptide Y), higher quality of life scores (role function/emotional function/cognitive function/social function/physical function), and lower pain severity scores (P<0.05).
Conclusion  : Hydroxycodone hydrochloride sustained-release tablets can effectively alleviate pain levels in patients with advanced malignant tumors, reduce levels of pain inducing factors, promote improvement in quality of life, and have high application value.